Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA)

被引:107
作者
Landfeldt, E. [1 ]
Strom, O. [1 ,2 ]
Robbins, S. [3 ]
Borgstrom, F. [1 ,2 ]
机构
[1] I3 Innovus, Stockholm, Sweden
[2] Karolinska Inst, Dept Learning Informat Management & Ethics, Med Management Ctr, Stockholm, Sweden
[3] Amgen Europe GmbH, Zug, Switzerland
关键词
Compliance; Fracture risk; Persistence; Retrospective; Sweden; Treatment patterns; BISPHOSPHONATE THERAPY; MEDICATION COMPLIANCE; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; DOSING FREQUENCY; BONE TURNOVER; PERSISTENCE; ALENDRONATE; RISK; EXPERIENCE;
D O I
10.1007/s00198-011-1549-6
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Osteoporosis treatments reduce the risk of fractures. The objective of this study was to investigate adherence to treatment of osteoporosis and its association to fractures in Sweden. Adherence to treatment of osteoporosis in Sweden is poor, and time on treatment was found to be significantly associated with fracture incidence. The objective of this study was to estimate persistence and compliance to treatment of primary osteoporosis in Sweden. A second aim was to investigate the determinants of non-persistence and the association between adherence and fracture incidence. Patients were identified through filled prescriptions for alendronate, risedronate, strontium ranelate, and raloxifene between 2005 and 2009 from the Swedish Prescribed Drug Register. Persistence was investigated using survival analysis. Medication possession ratio (MPR) was used to measure compliance in persistent patients. The outcome measure in the analysis of adherence and fracture incidence was hospitalized osteoporotic fractures. The final cohort consisted of 56,586 treatment-na < ve patients (mean age 71, 86% women). A total of 51%, 35%, 25%, and 14% were still on treatment (switching allowed) after 1, 2, 3, and 4 years, respectively. Average MPR in persistent patients was 94.2% (CI95 94.2-94.3%). Compared with < 1 month of therapy, treatment for 1 month to 1 year, 1 to 2 years, and 2 to 3 years was associated with a lower 3-year fracture incidence (HR 0.86, p = 0.091; HR 0.67, p < 0.001; and HR 0.59, p < 0.001, respectively). No significant relationship was identified between MPR and fracture risk. Persistence to treatment of osteoporosis in Sweden is poor and approximately 50% of all treatment-na < ve patients discontinue therapy within 1 year. Average refill compliance, estimated only while the patients were persistent, was found to be close to perfect. A strong association was identified between treatment persistence and fracture incidence, which calls for action to improve the current situation.
引用
收藏
页码:433 / 443
页数:11
相关论文
共 34 条
[1]
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[2]
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[3]
Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[4]
The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases [J].
Brankin, Eamonn ;
Walker, Mel ;
Lynch, Niall ;
Aspray, Terence ;
Lis, Yvonne ;
Cowell, Warren .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) :1249-1256
[5]
The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[6]
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey [J].
Carr, A. J. ;
Thompson, P. W. ;
Cooper, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1638-1644
[7]
A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[8]
A systematic review of persistence and compliance with bisphosphonates for osteoporosis [J].
Cramer, J. A. ;
Gold, D. T. ;
Silverman, S. L. ;
Lewiecki, E. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) :1023-1031
[9]
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [J].
Cramer, JA ;
Amonkar, MM ;
Hebborn, A ;
Altman, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) :1453-1460
[10]
RELATIONSHIP BETWEEN MEDICATION COMPLIANCE AND MEDICAL OUTCOMES [J].
CRAMER, JA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 :S27-S29